Comorbid alcoholism and depression: Treatment issues

M. E. Thase, Ihsan M Salloum, J. D. Cornelius

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Unless there is decisive professional intervention, people who suffer from both a depressive disorder and alcoholism are at great risk of chronic impairment, both at home and in the workplace; persistent symptomatic misery; and premature death. Untreated alcoholism intensifies depressive states, decreases responsiveness to conventional therapeutics, and increases the likelihood of suicide, suicide attempts, and other self-destructive behavior. During the past decade, evidence has emerged from placebo-controlled studies supporting the utility of tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) for treatment of depressed alcoholics. The superior safety and tolerability of SSRIs provide strong justification for their first-line use despite higher drug acquisition costs. Evidence has similarly emerged concerning the use of several novel pharmacotherapies and focused psychotherapies for people with alcoholism. These newer therapeutic options complement more traditional intervention such as chemical dependence counseling, disulfiram, and Alcoholics Anonymous so that it is now possible for a majority of depressed alcoholics to be treated effectively. The availability of effective treatments provides further impetus for health care professionals to improve recognition of comorbid alcoholism and depressive disorders. Improved recognition and treatment will save lives, and the benefits are likely to extend across generations.

Original languageEnglish
Pages (from-to)32-41
Number of pages10
JournalJournal of Clinical Psychiatry
Volume62
Issue numberSUPPL. 20
StatePublished - Oct 11 2001
Externally publishedYes

Fingerprint

Alcoholism
Depression
Serotonin Uptake Inhibitors
Alcoholics
Depressive Disorder
Suicide
Alcoholics Anonymous
Therapeutics
Disulfiram
Self-Injurious Behavior
Drug Costs
Premature Mortality
Tricyclic Antidepressive Agents
Psychotherapy
Workplace
Counseling
Placebos
Delivery of Health Care
Safety
Drug Therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Thase, M. E., Salloum, I. M., & Cornelius, J. D. (2001). Comorbid alcoholism and depression: Treatment issues. Journal of Clinical Psychiatry, 62(SUPPL. 20), 32-41.

Comorbid alcoholism and depression : Treatment issues. / Thase, M. E.; Salloum, Ihsan M; Cornelius, J. D.

In: Journal of Clinical Psychiatry, Vol. 62, No. SUPPL. 20, 11.10.2001, p. 32-41.

Research output: Contribution to journalArticle

Thase, ME, Salloum, IM & Cornelius, JD 2001, 'Comorbid alcoholism and depression: Treatment issues', Journal of Clinical Psychiatry, vol. 62, no. SUPPL. 20, pp. 32-41.
Thase, M. E. ; Salloum, Ihsan M ; Cornelius, J. D. / Comorbid alcoholism and depression : Treatment issues. In: Journal of Clinical Psychiatry. 2001 ; Vol. 62, No. SUPPL. 20. pp. 32-41.
@article{f8948b584b3d4dcc81709942f714c34b,
title = "Comorbid alcoholism and depression: Treatment issues",
abstract = "Unless there is decisive professional intervention, people who suffer from both a depressive disorder and alcoholism are at great risk of chronic impairment, both at home and in the workplace; persistent symptomatic misery; and premature death. Untreated alcoholism intensifies depressive states, decreases responsiveness to conventional therapeutics, and increases the likelihood of suicide, suicide attempts, and other self-destructive behavior. During the past decade, evidence has emerged from placebo-controlled studies supporting the utility of tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) for treatment of depressed alcoholics. The superior safety and tolerability of SSRIs provide strong justification for their first-line use despite higher drug acquisition costs. Evidence has similarly emerged concerning the use of several novel pharmacotherapies and focused psychotherapies for people with alcoholism. These newer therapeutic options complement more traditional intervention such as chemical dependence counseling, disulfiram, and Alcoholics Anonymous so that it is now possible for a majority of depressed alcoholics to be treated effectively. The availability of effective treatments provides further impetus for health care professionals to improve recognition of comorbid alcoholism and depressive disorders. Improved recognition and treatment will save lives, and the benefits are likely to extend across generations.",
author = "Thase, {M. E.} and Salloum, {Ihsan M} and Cornelius, {J. D.}",
year = "2001",
month = "10",
day = "11",
language = "English",
volume = "62",
pages = "32--41",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 20",

}

TY - JOUR

T1 - Comorbid alcoholism and depression

T2 - Treatment issues

AU - Thase, M. E.

AU - Salloum, Ihsan M

AU - Cornelius, J. D.

PY - 2001/10/11

Y1 - 2001/10/11

N2 - Unless there is decisive professional intervention, people who suffer from both a depressive disorder and alcoholism are at great risk of chronic impairment, both at home and in the workplace; persistent symptomatic misery; and premature death. Untreated alcoholism intensifies depressive states, decreases responsiveness to conventional therapeutics, and increases the likelihood of suicide, suicide attempts, and other self-destructive behavior. During the past decade, evidence has emerged from placebo-controlled studies supporting the utility of tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) for treatment of depressed alcoholics. The superior safety and tolerability of SSRIs provide strong justification for their first-line use despite higher drug acquisition costs. Evidence has similarly emerged concerning the use of several novel pharmacotherapies and focused psychotherapies for people with alcoholism. These newer therapeutic options complement more traditional intervention such as chemical dependence counseling, disulfiram, and Alcoholics Anonymous so that it is now possible for a majority of depressed alcoholics to be treated effectively. The availability of effective treatments provides further impetus for health care professionals to improve recognition of comorbid alcoholism and depressive disorders. Improved recognition and treatment will save lives, and the benefits are likely to extend across generations.

AB - Unless there is decisive professional intervention, people who suffer from both a depressive disorder and alcoholism are at great risk of chronic impairment, both at home and in the workplace; persistent symptomatic misery; and premature death. Untreated alcoholism intensifies depressive states, decreases responsiveness to conventional therapeutics, and increases the likelihood of suicide, suicide attempts, and other self-destructive behavior. During the past decade, evidence has emerged from placebo-controlled studies supporting the utility of tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) for treatment of depressed alcoholics. The superior safety and tolerability of SSRIs provide strong justification for their first-line use despite higher drug acquisition costs. Evidence has similarly emerged concerning the use of several novel pharmacotherapies and focused psychotherapies for people with alcoholism. These newer therapeutic options complement more traditional intervention such as chemical dependence counseling, disulfiram, and Alcoholics Anonymous so that it is now possible for a majority of depressed alcoholics to be treated effectively. The availability of effective treatments provides further impetus for health care professionals to improve recognition of comorbid alcoholism and depressive disorders. Improved recognition and treatment will save lives, and the benefits are likely to extend across generations.

UR - http://www.scopus.com/inward/record.url?scp=0034816697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034816697&partnerID=8YFLogxK

M3 - Article

C2 - 11584873

AN - SCOPUS:0034816697

VL - 62

SP - 32

EP - 41

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 20

ER -